Telehealth Weight Loss/GLP-1 Prescribing: What Prescribers Can Do in Illinois

Look, let’s cut through the noise: If you’re a psychiatrist or PMHNP watching the GLP-1 craze and wondering if you can (or should) prescribe semaglutide for weight loss — the short answer is yes, with some big caveats depending on where you practice and how you position it.

Weight management and mental health aren’t separate universes. Many of your patients struggle with medication-induced weight gain from antipsychotics or mood stabilizers. Others deal with emotional eating, binge eating disorder, or obesity that worsens their depression and anxiety. The rise of GLP-1 receptor agonists like Wegovy, Ozempic, and Mounjaro has opened a new frontier — and psychiatric providers are uniquely positioned to integrate metabolic care into their practice.

But here’s the reality check: state laws on prescribing authority vary wildly, especially for nurse practitioners. Telehealth rules add another layer of complexity — some states ban controlled-substance prescribing via telemedicine for weight loss entirely. And if you’re not careful about documentation, follow-up protocols, and scope-of-practice boundaries, you could face board scrutiny.

This guide breaks down everything you need to know: the clinical rationale for psychiatrists treating obesity, the state-by-state prescribing rules (focusing on CA, TX, FL, NY, PA, and IL), telehealth compliance traps, reimbursement realities, and how platforms like Klarity Health remove the guesswork by handling patient acquisition and infrastructure while you focus on care.

Why Psychiatrists Are (Increasingly) Prescribing GLP-1s for Weight Loss

The Metabolic-Psychiatric Connection

Traditionally, psychiatrists stuck to psychotropics — SSRIs, antipsychotics, mood stabilizers. Weight management was ‘someone else’s job.’ But that division is crumbling. Here’s why:

Your patients already have metabolic issues you’re managing. If you prescribe olanzapine or quetiapine, you’re monitoring glucose and lipids because those drugs cause weight gain and metabolic syndrome. You’re already ordering labs, counseling on diet, maybe prescribing metformin to counteract antipsychotic-induced diabetes risk. Prescribing a GLP-1 to help a patient lose 30 pounds they gained on your psychiatric meds? That’s not scope creep — that’s comprehensive care.

Obesity and mental health feed each other. Depression increases obesity risk (through inactivity, stress eating, medication side effects). Obesity worsens depression (through inflammation, poor self-image, social stigma). Treating one without addressing the other is like bailing water from a leaking boat. Psychiatrists who integrate weight management see better outcomes across the board — improved mood, better medication adherence, reduced cardiovascular risk.

GLP-1s may have direct mental health benefits. Emerging research shows GLP-1 agonists reduce inflammation and modulate brain reward pathways. Patients report decreased cravings (not just for food — some studies show reduced alcohol and substance cravings). While not FDA-approved for psychiatric conditions yet, the mechanisms are being studied for binge eating disorder, substance use disorders, even depression itself.

Dr. Elliott Lewis, a psychiatrist who’s also board-certified in obesity medicine, puts it this way: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ He’s not alone — more psychiatrists are pursuing dual certification in obesity medicine to formalize this competency.

Is It Within Scope? The Training Question

The pushback usually sounds like: ‘I’m not trained in endocrinology. Isn’t prescribing weight-loss drugs outside my scope?’

Here’s the nuance: Scope of practice is about competency, not specialty titles. You already manage general medical issues in psychiatry — checking thyroid function before diagnosing depression, treating hypertension caused by stimulants, managing lithium-induced hypothyroidism. If you gain the knowledge to safely prescribe GLP-1s (through CME, mentorship, or certification), it’s within your scope.

Many psychiatrists are obtaining American Board of Obesity Medicine (ABOM) certification — which is open to physicians of any specialty. The pathway involves ~60 hours of obesity-focused CME covering metabolic physiology, nutrition, pharmacotherapy, and behavioral interventions, followed by a board exam. This demonstrates formal competency and addresses any scope concerns head-on.

Even without ABOM certification, psychiatrists can prescribe weight-loss medications if they:

• Understand the pharmacology, indications, and contraindications
• Document appropriate patient selection (BMI criteria, ruling out secondary causes of obesity)
• Monitor for side effects and adjust treatment accordingly
• Collaborate or communicate with the patient’s primary care provider when needed

Bottom line: You don’t need to become an endocrinologist. You need to be competent in the specific intervention you’re offering — and for many patients, especially those on psychiatric medications affecting weight, this intervention makes clinical sense.

The Safety Question: Do GLP-1s Cause Psychiatric Issues?

The big scare in 2023-2024 was reports of suicidal ideation linked to Ozempic and Wegovy. Understandably, psychiatric providers got nervous.

The data is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. Regulatory agencies (FDA, EMA) reviewed the reports and found no causal link. In fact, GLP-1-treated groups in the STEP trials showed slightly lower rates of depressive symptoms compared to controls — likely due to weight loss improving quality of life.

For psychiatrists, this means: monitor mental health as you would with any patient, but don’t avoid GLP-1s out of fear. Document baseline mood and check in regularly. If a patient has active suicidal ideation or severe untreated depression, stabilize that first — but obesity itself isn’t a contraindication.

Side effects to watch: nausea (very common initially), GI issues, rare pancreatitis. Psych-specific considerations include ensuring patients aren’t using GLP-1s as a quick fix while avoiding necessary therapy for eating disorders.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

PMHNP vs. Psychiatrist: Who Can Prescribe Weight-Loss Meds Where?

This is where things get messy. Psychiatrists (MD/DO) have full prescriptive authority in all 50 states. If you’re an MD, you can prescribe semaglutide, liraglutide, phentermine, or any FDA-approved weight-loss medication anywhere, subject to standard medical regulations and state-specific prescribing protocols (more on those in a minute).

Psychiatric Nurse Practitioners face a patchwork of state laws. Your ability to prescribe weight-loss medications — especially controlled substances like phentermine — depends entirely on your state’s scope-of-practice rules.

Full Practice Authority (FPA) States

About 26 states plus D.C. grant NPs full practice authority, meaning you can evaluate, diagnose, and prescribe independently without physician oversight. Examples include:

• Illinois (after 4,000 hours experience + 250 CE hours)
• New York (after 3,600 hours supervised practice)
• Washington, Oregon, Colorado, Arizona, New Mexico (immediate FPA)

In FPA states, a PMHNP can prescribe GLP-1s (non-controlled) and even controlled weight-loss drugs like phentermine independently — but (and this is a big but) you must practice within your competency. If your training is purely psychiatric and you haven’t done additional education in obesity medicine, prescribing weight-loss meds to otherwise healthy patients could be challenged as outside your scope.

Practical workaround: Many PMHNPs in FPA states limit weight-loss prescribing to patients they’re already treating for mental health conditions — addressing obesity as a comorbidity or medication side effect. This keeps it clearly within psychiatric scope.

Also note: Even in FPA states, some insurers and pharmacies require physician sign-off for high-cost GLP-1 prescriptions or may deny coverage for NP-prescribed medications without an MD involved. It’s not a legal barrier, but an operational one that some telehealth platforms solve by having an MD medical director review cases.

Restricted/Collaborative Practice States

The other half of states require NPs to have a collaborative practice agreement or physician supervision to prescribe. Key examples:

Texas: Strictly collaborative. All NPs must have a written Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. The PAA must specify what medications you can prescribe (including controlled substances by schedule), require monthly quality review meetings, and detail chart review processes. One physician can supervise up to 7 NPs. For weight-loss prescribing, the PAA should explicitly authorize obesity medications.

Florida: APRNs must have a supervising physician protocol. Florida’s ‘Autonomous Practice’ license exists but is limited to primary care NPs (family, adult-gero, pediatric) and excludes PMHNPs entirely. Even autonomous NPs can’t prescribe controlled substances independently. So if you’re a PMHNP in Florida, you need an MD collaborator to prescribe anything for weight loss. Additionally, Florida bans telehealth prescribing of controlled substances (like phentermine) except for psychiatric treatment, inpatient care, or addiction medicine — and weight loss doesn’t qualify. You can prescribe non-controlled GLP-1s via telehealth, but not phentermine.

Pennsylvania: CRNPs need a collaborative agreement with a physician. The physician doesn’t have to be on-site, but prescriptions must list both the CRNP’s name and the collaborating physician’s name. The agreement should outline what drugs the NP can prescribe; one physician can collaborate with up to 4 NPs.

California: Currently transitioning. AB 890 allows experienced NPs to practice independently after a 3-year/4,600-hour supervised transition period (started 2023, full implementation 2026). Until then, NPs need physician ‘standardized procedures’ to prescribe. Even with independence, California’s Corporate Practice of Medicine law means only physicians can own medical practices — so NP-owned weight-loss clinics must use MSO structures with physician oversight. Plus, NPs still can’t independently prescribe controlled substances for weight loss until they obtain full independent furnishing privileges under AB 890.

Controlled Substances: The Phentermine Problem

Phentermine (brand names Adipex-P, Lomaira) is a Schedule IV stimulant commonly prescribed for short-term weight loss. It’s popular because it’s cheaper than GLP-1s and has decades of use. But prescribing it remotely is a compliance minefield.

Federal law (Ryan Haight Act) traditionally required an in-person exam before prescribing any controlled substance. COVID waivers lifted this — the DEA’s current extension (through end of 2025) allows teleprescribing of controlled substances without a prior in-person visit. However, state laws can override federal rules.

States like Florida and Alabama explicitly prohibit teleprescribing controlled substances for weight loss. Even with federal permission, a Florida telehealth provider writing phentermine for a patient is violating state law and risks license action.

Workaround: Many telehealth weight-loss programs simply avoid controlled substances and stick to GLP-1s (semaglutide, tirzepatide, liraglutide) which are not controlled and face fewer restrictions. This also sidesteps the 30-90 day limits many states impose on controlled-substance prescriptions.

State-by-State Prescribing Protocols for Weight Loss

Beyond scope-of-practice rules, several states have specific regulations for prescribing weight-loss medications. These apply to MDs and NPs equally (though NPs must follow them within their collaborative framework).

Florida: The Strictest Playbook

Florida’s Board of Medicine Rule 64B15-14.004 (mirrored for DOs and APRNs) lays out detailed requirements:

Patient Eligibility:

• BMI ≥30, or BMI ≥25 with comorbidity (diabetes, hypertension, sleep apnea, etc.)
• Body fat percentage above defined cutoffs (alternative to BMI)

Before Prescribing:

• Comprehensive history and physical exam (can be delegated to an APRN or PA under supervision, but must be documented)
• Labs to rule out secondary causes (thyroid, etc.)
• Written informed consent from patient about risks/benefits
• Provide the state’s Weight-Loss Consumer Bill of Rights brochure

Ongoing Requirements:

• Follow-up visit at least every 3 months for patients on obesity medications (can be telehealth)
• Document weight, vital signs, tolerance, progress at each visit
• Adjust or discontinue if no progress after 3-6 months or if side effects occur

Restrictions:

• No prescribing ‘serotonergic anorectics’ unless FDA-approved for obesity (aimed at off-label SSRI use)
• Controlled substances for weight loss cannot be prescribed via telehealth under Florida’s telehealth law (F.S. 456.47) — limited exceptions for psychiatric disorders, but weight loss alone doesn’t qualify

Penalties: Florida actively enforces this. Clinics have been cited for failing to do quarterly follow-ups, prescribing to patients below BMI thresholds, or not documenting informed consent. Fines and license suspension are on the table.

New Jersey: Comprehensive Workup Required

NJ regulations (N.J.A.C. 13:35-7A.5) require prescribers to:

• Conduct a full physical exam and history before initiating weight-loss meds
• Order appropriate lab tests (metabolic panel, lipids, thyroid, etc.)
• Assess and treat any psychiatric conditions prior to or alongside weight-loss treatment (this actually favors psychiatrists — you’re already doing this)
• Provide or refer for nutritional counseling, exercise planning, and behavior modification — can’t just hand out pills
• Document ongoing monitoring at every visit

NJ’s emphasis on mental health screening and multimodal treatment aligns well with psychiatric practice. A PMHNP or psychiatrist addressing a patient’s depression and obesity simultaneously is exactly what NJ regulators want to see.

Virginia: Frequent Early Follow-Ups

Virginia Board of Medicine requires:

• Initial in-person or telehealth exam documenting indication
• Follow-up within 30 days of starting treatment, then monthly for the first few months
• Document a diet and exercise program for the patient
• Applies mainly to controlled substances for weight loss

For telehealth, this means scheduling at least monthly video check-ins initially — ensures close monitoring but also creates consistent billable visits.

Mississippi: Off-Label GLP-1 Ban

Unique to Mississippi (as of Aug 2023): The state medical board prohibits off-label prescribing of GLP-1 agonists for weight loss. You must use the FDA-approved weight-loss versions (Wegovy, Saxenda) — not diabetes versions (Ozempic, Mounjaro) — unless treating diabetes. This was a response to shortages and safety concerns. Providers in Mississippi prescribing Ozempic off-label for obesity risk discipline.

States Without Specific Obesity Rules

California, Texas, New York, Pennsylvania, Illinois don’t have granular obesity-prescribing regulations like Florida or NJ. Instead, they rely on general standards of care. That said:

• Texas prohibits Schedule II stimulants (amphetamines) for weight loss, but phentermine (IV) and GLP-1s are fine
• All states expect appropriate indications (BMI criteria per FDA labeling) and monitoring; failure to do so could be deemed unprofessional conduct
• PDMP checks are required in almost all states for controlled substances (including phentermine)

Best practice everywhere: Document BMI, comorbidities, informed consent, a treatment plan including lifestyle changes, and regular follow-ups. Even if your state doesn’t mandate quarterly visits, doing them protects you medically and legally.

Telehealth Compliance: Federal Waivers vs. State Traps

Telehealth exploded during COVID, and prescribing rules relaxed — but the regulatory landscape in 2026 is a minefield of conflicting federal and state laws.

Federal Green Light (Mostly)

The DEA’s temporary extension (through Dec 31, 2025, likely renewed into 2026) allows providers to prescribe controlled substances via telehealth without a prior in-person exam. This was a lifeline for ADHD stimulant prescribing, buprenorphine for addiction, and yes, phentermine for weight loss.

But federal permission doesn’t override state prohibition. The DEA explicitly states teleprescribing is only allowed if also permitted under state law.

State Red Lights

A small but critical group of states ban or severely restrict controlled-substance prescribing via telehealth:

Florida: No controlled substances via telehealth except for psychiatric disorders, inpatient care, hospice, or addiction treatment. Weight loss doesn’t qualify, so phentermine via telehealth to a Florida patient is illegal under state law, regardless of federal waivers. (GLP-1s, being non-controlled, are fine.)

Alabama: Requires an in-person exam for controlled substances; teleprescribing restricted.

South Carolina, Idaho: Have strict telemedicine standards that effectively require in-person exams for controlled drugs.

Approximately 8 states maintain these restrictions as of 2026. Telehealth platforms must geofence services or arrange one-time in-person exams to comply.

Telehealth Best Practices for Weight Loss

To stay compliant:

1. Video consult for initial visit. Don’t rely on questionnaires alone. A Mississippi doctor lost his license in 2023 for prescribing Ozempic via instant messaging with no video. Visual exam demonstrates standard of care.

2. Check PDMP before prescribing controlled substances. Most states mandate this (Florida’s E-FORCSE, Texas PMP, Illinois PMP, etc.). Integrate PDMP checks into your telehealth workflow electronically.

3. Document thoroughly. Record vitals (patient-reported or via connected devices), BMI calculation, discussion of risks/benefits, lifestyle counseling provided, and follow-up plan. This satisfies state rules like Florida’s exam requirement and protects you in audits.

4. Schedule regular follow-ups. Even if not state-mandated, quarterly check-ins align with clinical guidelines and ensure patients stay on track. Plus, more visits = more revenue.

5. Use FDA-approved products. Avoid compounded semaglutide unless there’s a legitimate shortage and your pharmacy uses FDA-sanctioned ingredients. Alabama and other states have warned against non-FDA-registered compounded GLP-1s.

6. License in every state you practice. Out-of-state telehealth providers must hold a license (or meet telehealth registration requirements) in the patient’s state. Florida, Texas, and others enforce this strictly.

Reimbursement: Can You Actually Get Paid for This?

Weight-loss medication management is increasingly reimbursable — a shift from when it was purely cash-pay.

Medication Coverage: The GLP-1 Gold Rush

Private insurance: Many commercial plans now cover GLP-1 weight-loss drugs (Wegovy, Saxenda, and tirzepatide when approved) with prior authorization. Requirements typically include:

• BMI ≥30, or ≥27 with comorbidity
• Documentation of lifestyle modification attempts (diet, exercise programs)
• Prescriber attestation that patient will use medication as part of comprehensive plan

PAs can be tedious, but they’re doable. Some insurers impose quantity limits — e.g., BCBS Texas limited new GLP-1 prescriptions to 30-day supplies initially (as of late 2024) to monitor adherence and prevent waste.

Medicare/Medicaid: Historically, Medicare excluded weight-loss drugs. This is changing. In late 2024, the Biden administration proposed Medicare coverage for anti-obesity medications. By November 2025, federal officials announced Medicare will begin covering GLP-1 weight-loss drugs starting in 2026 under negotiated pricing with manufacturers. This opens the market to millions of Medicare beneficiaries.

State Medicaid programs vary — some already cover at least one GLP-1 for obesity; others will expand coverage following Medicare’s lead. For providers, this means patients who couldn’t afford $1,300/month out-of-pocket can now access treatment through insurance.

Visit Reimbursement: Billing for Weight Management

For the clinical encounter, use standard E/M codes (99202-99215 for outpatient visits) or psychiatric evaluation codes (90792 for initial, 90833/90836 for therapy + med management). If the visit is purely weight management, code based on complexity — reviewing labs, counseling on diet/exercise, adjusting medication could justify a level 3 or 4 visit.

Medicare reimbursement: Psychiatrists bill at 100% of physician fee schedule rates. A routine 15-minute med management visit (99213) pays ~$75-120 depending on locality. Initial evaluations (90792) can pay ~$200. PMHNPs are reimbursed at 85% of physician rates under Medicare when billing under their own NPI.

Telehealth parity: Many states mandate equal payment for telehealth vs. in-person visits. California, New York, Illinois, Pennsylvania have parity laws for commercial plans. Medicare extended telehealth reimbursement at office rates (non-facility) through at least 2025. This means a telepsych med check pays the same as an office visit.

State Medicaid: Illinois Medicaid reimburses APRNs at 100% of physician rates — a huge win for NPs. Other states typically pay 85-100% depending on the program.

Obesity-Specific Billing Codes

CMS offers G0447 (15 minutes of face-to-face obesity counseling for BMI ≥30) and G0473 (group sessions). These are often used by primary care or dietitians. Psychiatrists could use G0447 if providing dietary counseling, but in practice, time-based E/M coding is simpler if you’re combining weight management with psychiatric care.

Coding Tips

• Use obesity as primary diagnosis (ICD-10 E66.x) when billing weight management visits — facilitates coverage.
• Add telehealth modifier 95 or POS code 02 for parity payment.
• Document complexity: lifestyle counseling provided, medication side effects discussed, labs reviewed, comorbidities addressed. Justifies higher-level E/M codes.
• For phentermine (controlled substance), document PDMP check and clinical rationale to satisfy audits.

Cash-Pay Alternative

Many telehealth weight-loss companies operate on a subscription or cash-pay model (monthly fees ranging from $99-300 including medication). This avoids insurance hassles but limits your market to affluent patients or those willing to pay out-of-pocket. As insurance coverage expands, expect a shift toward insured patients.

The Klarity Advantage: Patient Acquisition Without the Marketing Gamble

Here’s the economic reality most providers face when trying to build a weight-loss practice: patient acquisition is expensive and uncertain.

DIY marketing — SEO, Google Ads, directory listings — sounds appealing until you run the numbers:

• SEO takes 6-12 months of consistent content and technical investment before you see meaningful patient flow. You’re paying an agency $2,000-5,000/month with zero guaranteed results for the first half-year.
• Google Ads for mental health keywords run $15-40+ per click. Most clicks don’t convert. A realistic cost per booked patient through PPC is $200-400+ when you factor in ad spend, testing, optimization, and wasted clicks.
• Directory listings like Psychology Today or Zocdoc charge monthly fees ($30-100/month) AND you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+ per lead) — so you’re paying both subscription and per-patient fees.
• Total monthly cost: If you’re running a multi-channel strategy (SEO, PPC, directories, maybe social media), expect $3,000-5,000/month minimum with uncertain ROI. Most solo providers don’t have the budget, expertise, or patience.

Klarity Health takes a different approach: a pay-per-appointment model (similar to Zocdoc) where you pay a standard listing fee per new patient lead, with no upfront marketing spend or monthly subscription fees.

The value proposition:

1. Pre-qualified patients. Klarity matches patients to your specialty (psychiatric med management, weight loss if you offer it) and availability. You’re not wasting time on no-shows from cold leads.

2. No marketing risk. Instead of gambling $5,000/month on ads that might not work, you pay only when a qualified patient books. Guaranteed ROI.

3. Built-in telehealth infrastructure. No need to pay for separate platform licenses (Doxy.me, SimplePractice, etc.). Klarity provides the tech.

4. Insurance and cash-pay patient flow. Unlike some platforms that are cash-only, Klarity connects you with both insured patients (for whom you can bill insurance at full rates) and self-pay patients.

5. You control your schedule. Set your availability, accept patients you’re comfortable treating, and scale up or down without being locked into a contract.

The economics: Let’s say Klarity charges a $X listing fee per new patient (similar to Zocdoc’s model). If that patient becomes an ongoing med management patient who sees you monthly for 6-12 months at $100-150 per visit (insurance reimbursement), your lifetime value from one patient is $600-1,800. The acquisition cost is a one-time fee, not a recurring monthly ad budget.

Compare that to spending $4,000/month on marketing to generate 10-15 new patients (if you’re lucky and your campaigns work). With Klarity, you pay a fraction of that and only for patients who actually show up.

For weight-loss specifically: Klarity’s patient matching can surface individuals seeking both psychiatric care and weight management — addressing the dual diagnosis opportunity. You’re not building two separate practices (psych and obesity); you’re treating the whole patient.

Practical Scenarios: When Psychiatrists and PMHNPs Should (and Shouldn’t) Prescribe Weight Loss Meds

Good fit:

• Antipsychotic-induced weight gain: Patient on olanzapine gained 40 pounds, now pre-diabetic. Adding metformin helped a bit, but patient wants more. Prescribing semaglutide to reverse metabolic harm from your psych meds? Absolutely within scope and medically indicated.

• Comorbid depression and obesity: Patient with major depressive disorder and BMI 35. Weight worsens self-esteem and limits activity. Treating both with antidepressant + GLP-1 + therapy addresses root causes. You’re the ideal provider because you understand the bidirectional relationship.

• Binge eating disorder: Patient meets criteria for BED, struggles with compulsive eating. While therapy (CBT) is first-line, GLP-1s show promise in reducing cravings. Combining medication with therapy in your practice is evidence-based.

• Medication optimization: Patient on multiple psych meds, weight is a barrier to adherence. They want to stop meds because of weight gain. Offering GLP-1 as part of a plan to continue necessary psychiatric treatment (while addressing weight) improves overall outcomes.

Proceed with caution:

• No psychiatric indication: Otherwise healthy patient seeking GLP-1 purely for cosmetic weight loss, no mental health issues. If you haven’t done additional training in obesity medicine, this feels like scope stretch. Better to refer or pursue ABOM certification first.

• Eating disorders without treatment: Patient with active anorexia or bulimia requesting weight-loss meds. This is contraindicated — stabilize the eating disorder first with appropriate specialist care.

• States with strict collaboration requirements (if you’re an NP): PMHNP in Texas or Florida wanting to prescribe phentermine via telehealth without an MD collaborator. Not going to fly legally. Either partner with a physician or stick to non-controlled GLP-1s (and even then, ensure your collaborative agreement covers it).

Red flags to refuse:

• Patient shopping for controlled stimulants with vague weight concerns (potential diversion risk)
• Requesting off-label use banned in your state (e.g., Ozempic for weight loss in Mississippi)
• Unwillingness to engage in lifestyle changes or follow-up visits (weight-loss meds aren’t magic pills; need comprehensive treatment)

State Comparison Table: Quick Reference

FAQs: Weight-Loss Prescribing for Psychiatric Providers

Q: Can a psychiatrist prescribe Wegovy or Ozempic for weight loss?

A: Yes, psychiatrists (MD/DO) can prescribe GLP-1 agonists for weight loss in any state, provided they meet standard medical practice requirements: appropriate patient selection (BMI criteria per FDA labeling), informed consent, monitoring, and documentation. Some psychiatrists pursue additional training (like ABOM certification) to formalize their competency, but it’s not legally required. Just ensure you follow any state-specific protocols (e.g., Florida’s quarterly follow-ups).

Q: Can a PMHNP prescribe phentermine for weight loss?

A: It depends on the state. In full practice authority states (like Illinois, Washington, Oregon), an experienced PMHNP can prescribe phentermine (a Schedule IV controlled substance) independently, though you should ensure it’s within your competency. In restricted/collaborative states (Texas, Florida, Pennsylvania), you need a physician’s delegation or supervision — your collaborative agreement must explicitly authorize controlled-substance prescribing for weight management. In Florida specifically, you cannot prescribe phentermine via telehealth for weight loss (state law bans it).

Q: Is prescribing weight-loss medications within a psychiatric NP’s scope of practice?

A: It can be, with caveats. Your scope is defined by your training and competency, not rigidly by specialty. Many PMHNPs justify weight-loss prescribing when it’s part of treating a psychiatric patient (e.g., managing antipsychotic-induced weight gain, addressing obesity comorbid with depression). If you’re marketing a standalone weight-loss clinic to the general public with no mental health component, some state boards might question whether you’re practicing outside your specialty training. Best practice: pursue supplemental education in obesity medicine (CME courses, ABOM modules) and/or limit weight-loss treatment to patients under your psychiatric care.

Q: What are the risks of prescribing GLP-1s via telehealth?

A: GLP-1s (semaglutide, tirzepatide, liraglutide) are not controlled substances, so they avoid the Ryan Haight Act restrictions and most state telehealth bans. The main risks are:

• Inadequate evaluation: Relying solely on questionnaires without a video consult can fail to meet standard of care and state requirements (like Florida’s ‘comprehensive exam’ rule). Always do at least a video visit initially.
• Failure to monitor: States like Florida and Virginia mandate regular follow-ups. Skipping them exposes you to board discipline.
• Off-label issues: Prescribing diabetes-version GLP-1s (Ozempic) for weight loss is off-label and banned in Mississippi. Use FDA-approved obesity versions (Wegovy, etc.) where possible.
• Compounding pharmacy problems: Using non-FDA-registered compounded semaglutide can violate state pharmacy laws. Stick to FDA-approved products or ensure your compounding pharmacy complies with regulations.

Q: How much can I realistically earn from weight-loss medication management?

A: Per visit: If billing insurance, a 15-20 minute med check (E/

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting